Significance of regular review 1. Keep abreast of changes in the disease 2. Recurrence? New tumor? 3.Toxic side effects and complications of treatment 4.Patients’ survival and quality of life Peak of recurrence The time curve of risk of recurrence after breast cancer surgery is bimodal, appearing in the second and fifth year after surgery, and the superimposed effect is more obvious in patients with axillary lymph node metastasis and larger tumor diameter. For patients with postoperative breast cancer, the NCCN guidelines recommend: 1. follow-up and physical examination every 4-6 months for 5 years and every 12 months thereafter 2. annual mammogram 3. gynecologic examination (gynecologic ultrasound for endometrium) every 12 months if the uterus is still preserved for those who received TAM 4. treatment with aromatase inhibitors (letrozole, anastrozole, exemestane) or existing treatment. Exemestane) therapy or patients with ovarian failure (hormones up to menopausal levels) due to existing therapy should be monitored for bone mineral density at baseline status and periodically thereafter. Review items: 1. history and physical examination 2. complete blood count 3. liver function 4. chest imaging (X-ray and/or CT) 5. bone scan 6. x-ray of long bones and weight-bearing bones with symptomatic bone and abnormal bone scan 7. consider abdominal CT or MRI 8. biopsy should be performed at first recurrence 9. if tumor ER, PR and HER-2 status is unknown, initial test result is Consider re-examination to determine if the tumor is negative or not overexpressed 10. Genetic counseling for patients with high risk of hereditary breast cancer The panel believes that PET or PET/CT should not be routinely used in the evaluation of metastatic disease, unless other staging methods are ambiguous or questionable and biopsy of the suspected site is more likely to provide useful information. Mammography should be followed up closely according to clinical needs: 1. For breast-conserving patients, mammography should be performed once every 6-12 months after the completion of radiotherapy. For patients with mammography suggestive of atypical hyperplasia or non-benign calcification, follow-up should be performed 3-6 months according to the mammography prompt. Combined with the current research and Chinese national conditions, the following review protocol is better 1. 1-2 years after surgery: 1 review every 3-4 months 2. 3-5 years after surgery: 1 review every 6 months Review items: (from the 6th year after surgery: 1 review per year) 1. affected chest wall (affected breast for breast preservation): exclude local recurrence 2. contralateral breast: exclude contralateral metastasis 3. ultrasound of bilateral axillary and bilateral supraclavicular fossa: exclude common Lymphatic metastasis 4.Chest X-ray: to exclude lung metastasis 5.Liver and biliary ultrasound: to exclude liver metastasis 6.Gynecological ultrasound: to understand the endometrial condition (TAM) 7.Blood routine and liver biochemistry: to understand the toxic side effects of chemotherapy and other treatments 8.Tumor index: to assess the efficacy and monitor whether metastasis 9.Bone scan: without symptoms of bone metastasis, bone scan examination is usually not performed. 10.CT or MRI of chest and abdomen is not used as routine postoperative review. CT or MRI is feasible after positive screening of chest X-ray and abdominal ultrasound for further consultation. 11.Decreased bone density is one of the main adverse effects of endocrine therapy, and it is recommended to review bone density once a year. 12. CT or MRI of the head is usually performed only in patients with suspected brain metastases: the most common symptom of brain metastases: headache. The most typical headache occurs in the morning after waking up and before getting up, and is aggravated when coughing and bending and holding the breath. Other signs: behavioral changes, mental abnormalities.